Abstract Number: 1706 • 2012 ACR/ARHP Annual Meeting
Predictive Atherosclerotic Risk Factors At Inception in a Multicentre, Multinational Cohort
Background/Purpose: Patients with systemic lupus erythematosus (SLE) develop premature atherosclerosis (AS). This study examines predictive factors at inception for atherosclerotic vascular events (AVE) over…Abstract Number: 1707 • 2012 ACR/ARHP Annual Meeting
The Association of Serum Biomarkers and Metabolic Syndrome with Subclinical Atherosclerosis in Systemic Lupus Erythematosus: A Controlled Analysis in Patients with No Clinical Disease Activity
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of developing atherosclerotic cardiovascular disease (CVD). In addition to traditional CVD risk factors or…Abstract Number: 1708 • 2012 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Cardiovascular Risk Equation
Background/Purpose: Accelerated atherosclerosis remains the major late cause of death in SLE. Yet, the "traditional" cardiovascular risk equations (Framingham, Reynolds, SCORE) consistently underestimate the risk. …Abstract Number: 1709 • 2012 ACR/ARHP Annual Meeting
Biomarkers of Atherosclerosis Are Associated with Progression of Non-Cardiovascular Damage in Patients with SLE
Background/Purpose: Studies have shown that even after taking traditional cardiac risk factors into account, SLE patients have up to 50-fold higher risk of developing atherosclerotic…Abstract Number: 1710 • 2012 ACR/ARHP Annual Meeting
Increase in Vitamin D Improves Disease Activity and Systolic Blood Pressure in Systemic Lupus Erythematosus
Background/Purpose: Vitamin D deficiency has also been associated with different chronic conditions including cardiovascular diseases such as coronary artery disease, cardiac failure and hypertension. In…Abstract Number: 1711 • 2012 ACR/ARHP Annual Meeting
Association of Vascular Calcification and Perivascular Adipose Tissue of the Descending Aorta with Cardiovascular Events in SLE
Background/Purpose: Women with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease (CVD). We have shown that clinically CVD-free women with SLE have…Abstract Number: 1712 • 2012 ACR/ARHP Annual Meeting
The Submaximal Heart and Pulmonary Evaluation: A Novel Noninvasive Test to Identify Pulmonary Hypertension in Patients with Systemic Sclerosis
Background/Purpose: Pulmonary hypertension (PH), defined as a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg on right heart catheterization (RHC), is a leading cause of…Abstract Number: 1713 • 2012 ACR/ARHP Annual Meeting
Developing an Index for Disease Activity and Therapeutic Response in Connective Tissue Disease Related Interstitial Lung Disease: Results From A Delphi Exercise: Delivering A Consensus On Domains
Background/Purpose: Lack of reliable and valid measures of disease activity and clinical response in patients with connective tissue disease (CTD)-related interstitial lung disease (ILD) makes…Abstract Number: 1714 • 2012 ACR/ARHP Annual Meeting
Gender Differences in Systemic Sclerosis: Relationship to Disease Specific Clinical Manifestations and Estradiol Levels
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by inflammation, autoantibody production, and increased production of extracellular matrix (ECM), resulting in fibrosis. We…Abstract Number: 1715 • 2012 ACR/ARHP Annual Meeting
Imatinib Mesylate (Gleevec™) in the Treatment of Diffuse Cutaneous Systemic Sclerosis: Results of a 24 Month Open Label, Extension Phase
Background/Purpose: Imatinib mesylate (IM) has been shown to decrease fibrosis in preclinical models and is a treatment of interest for Systemic Sclerosis (SSc). We have…Abstract Number: 1716 • 2012 ACR/ARHP Annual Meeting
Outcomes Linked to Intensive Treatment Trials in Systemic Sclerosis
Background/Purpose: A number of clinical trials using intensive immunosuppression followed by autologous haematopoietic stem cell transplantation (HSCT) in systemic sclerosis (SSc) are underway or have…Abstract Number: 1677 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Intra-Articular Infliximab Therapy for Treatment Resistant Temporomandibular Joint Arthritis in Children
Background/Purpose: Temporomandibular joint (TMJ) arthritis occurs in as much as 80% of children with juvenile idiopathic arthritis (JIA) and can result in substantial facial deformity.…Abstract Number: 1678 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Adalimumab in Children with Active Polyarticular Juvenile Idiopathic Arthritis Aged 2 to <4 Years or ≥4 Years Weighing <15 Kg
Background/Purpose: Adalimumab (ADA) is approved for use in moderate to severe JIA in patients (pts) ≥4 yrs old in the US, EU,and Japan. ADA has…Abstract Number: 1679 • 2012 ACR/ARHP Annual Meeting
Cumulative Long-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis: Results up to 7 Years of Follow-up
Background/Purpose: We previously reported the efficacy and safety of abatacept (ABA) in patients with juvenile idiopathic arthritis (JIA) in the AWAKEN trial1, during the 4-month…Abstract Number: 1680 • 2012 ACR/ARHP Annual Meeting
Diagnostic Value of the Assessment of Spondyloarthropathy International Society (ASAS) Criteria for Children with Enthesitis Related Arthritis (ERA): A Single Center Study of 124 Patients
Background/Purpose: Enthesitis Related Arthritis (ERA) is a common subtype (36%) of Juvenile Idiopathic Arthritis (JIA) seen in India 1. These criteria do not distinguish between…